Sign up to save your podcasts
Or
Share Treatment of Metastatic Non-Small Cell Lung Cancer With Targeted Mutations
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Treatment of Metastatic Non-Small Cell Lung Cancer With Targeted Mutations
Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for metastatic non-small cell lung cancer (NSCLC) with actionable mutations in frontline therapy. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins Hospital.
In this episode, we covered:
• Common EGFR mutations and the latest treatment options, including osimertinib, amivantamab, and chemotherapy combinations.
• The importance of comprehensive NGS testing and the need for retesting at progression.
• Insights into managing side effects associated with various therapies, including the proactive management of cutaneous toxicities.
• Treatment strategies for less common mutations such as ALK, ROS1, BRAF, and RET, along with their respective targeted therapies.
• The role of immunotherapy in specific mutations and the importance of patient choice and preferences in treatment decisions.
Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice.
YouTube: https://youtu.be/LMYDAjZcn5w
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
View all episodes
By Oncology Brothers
4.9
4242 ratings
Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for metastatic non-small cell lung cancer (NSCLC) with actionable mutations in frontline therapy. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins Hospital.
In this episode, we covered:
• Common EGFR mutations and the latest treatment options, including osimertinib, amivantamab, and chemotherapy combinations.
• The importance of comprehensive NGS testing and the need for retesting at progression.
• Insights into managing side effects associated with various therapies, including the proactive management of cutaneous toxicities.
• Treatment strategies for less common mutations such as ALK, ROS1, BRAF, and RET, along with their respective targeted therapies.
• The role of immunotherapy in specific mutations and the importance of patient choice and preferences in treatment decisions.
Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice.
YouTube: https://youtu.be/LMYDAjZcn5w
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
121 Listeners
ASCO Daily News
57 Listeners
Pod Save America
87,390 Listeners
Core IM | Internal Medicine Podcast
1,145 Listeners
The ONS Podcast
205 Listeners
OncoPharm
187 Listeners
ASCO Guidelines
44 Listeners
OncLive® On Air
22 Listeners
Lung Cancer Considered
26 Listeners
Oncology Today with Dr Neil Love
60 Listeners
Oncology On The Go
4 Listeners
Blood Cancer Talks
48 Listeners
Two Onc Docs
193 Listeners
Oncology for the Inquisitive Mind
4 Listeners